Ascendis Pharma A/S
ASND
$170.80
-$0.12-0.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.05% | 25.05% | 21.61% | -24.89% | 189.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.05% | 25.05% | 21.61% | -24.89% | 189.00% |
| Cost of Revenue | 124.34% | -28.64% | 53.14% | -12.31% | 65.81% |
| Gross Profit | -8.43% | 33.89% | 15.88% | -29.61% | 208.65% |
| SG&A Expenses | 46.67% | 24.15% | 10.88% | 4.55% | 1.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.12% | -1.43% | -14.42% | -11.09% | -17.18% |
| Operating Income | -105.56% | 101.04% | 27.30% | 6.44% | 65.38% |
| Income Before Tax | 29.43% | 54.35% | 38.63% | 11.43% | -18.69% |
| Income Tax Expenses | -58.99% | -81.45% | 59.74% | 152.78% | 95.74% |
| Earnings from Continuing Operations | 30.00% | 56.16% | 38.24% | 10.93% | -19.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.00% | 56.16% | 38.24% | 10.93% | -19.59% |
| EBIT | -105.56% | 101.04% | 27.30% | 6.44% | 65.38% |
| EBITDA | -116.30% | 104.58% | 28.05% | 6.43% | 67.50% |
| EPS Basic | 33.65% | 58.52% | 39.59% | 12.68% | -17.93% |
| Normalized Basic EPS | 33.12% | 56.82% | 39.97% | 13.18% | -17.04% |
| EPS Diluted | 33.65% | 58.52% | 39.59% | 12.68% | -17.93% |
| Normalized Diluted EPS | 33.12% | 56.82% | 39.97% | 13.18% | -17.04% |
| Average Basic Shares Outstanding | 5.51% | 5.70% | 2.24% | 2.01% | 1.41% |
| Average Diluted Shares Outstanding | 5.51% | 5.70% | 2.24% | 2.01% | 1.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |